Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study

Phase 2 Completed 22 enrolled National Cancer Institute, Naples

NaSingle-groupOpen-labelTreatment

Summary

A monocentric window of opportunity study preceded by a safety run-in phase. The study population will include locally advanced colon patients (T3 or T4).

Timeline

Start: 2018-06-12
Primary completion: 2019-06-17
Completion: 2019-09-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	240 mg	—

Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study

Summary

Timeline

Drugs

Indications